Celltrion specializes in “biosimilars”—cheaper generic versions of the pricey “biologic” drugs that are among Big Pharma’s bestsellers. Wall Street analysts project that the firm could achieve up to 25% future annual growth, with sales in multiple markets. U.S. regulators approved this country’s first biosimilar in 2015. Since then, Celltrion and its partners have won FDA approval for copies of Johnson & Johnson’s anti-inflammatory treatment Remicade. And in early October, the team got an important preliminary thumbs-up from an FDA advisory panel for a biosimilar version of Roche’s blockbuster cancer drug Rituxan.
Incheon, South Korea
|Revenues ($M) (Past 12 Months)||$925|
|Profits ($M) (Past 12 Months)||$351|
|Market Value as of Oct. 10, 2018 ($M)||$31,360|